Bridgeworth’s Alexion Pharmaceuticals ALXN Stock Holding History

Bridgeworth’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-42	Closed	-$5K	–	596
2018 Q2	$5K	Buy	+42	New	+$4.91K	﹤0.01%	510

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bridgeworth's ALXN Position: Q3 2018 in Review

Bridgeworth sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 42 shares — an estimated $5K sold.

Bridgeworth first reported a position in ALXN in Q2 2018 and held it in 1 quarter. The position peaked at $5K in Q2 2018. 584 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

Bridgeworth reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Bridgeworth sold 42 Alexion Pharmaceuticals shares in Q3 2018, an estimated $5K.
Bridgeworth first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Bridgeworth's Alexion Pharmaceuticals position peaked at $5K in Q2 2018.
584 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Bridgeworth's 13F filing for Q3 2018, filed 13 Nov 2018.